Exposure to ≥250 mg/m² doxorubicin-equivalent anthracycline chemo tied to risk for CVD, heart failure.
Working group reviewed bone complications to form recommendations for management of bone health.
Burden of childhood cancers disproportionately affects populations in resource-limited settings.
A primary outcome measure for phase 1 of the trial is determining the safety of oral LOXO-292.
After phase 1, the study will expand in a second phase to test the efficacy of these drugs at the determine dosage.
Cancer survival has improved among adolescents and young adults (AYA), but survival disparities are reported.
Individuals with pediatric-onset inflammatory bowel disease (pIBD) have an increased risk for cancer and mortality.
Fewer chemotherapy cycles could decrease long-term morbidity for certain patients.
Will “cure-seeking behavior” for terminally ill children with cancer interfere with the integrated delivery of palliative care?
An investigation of a large performance improvement clinical database revealed that most individuals receiving CAR-T have diagnoses of ALL or large B-cell lymphoma.
For children with relapsed or refractory B-cell acute lymphoblastic leukemia, tisagenlecleucel was deemed cost-effective, yet long-term outcomes are still uncertain.
Researchers report on a retrospective cohort analysis that evaluated the long-term effects of vigorous exercise for survivors of childhood cancer.
Survivorship plans for adolescent and young adult survivors need to consider the relative long-term survival for AYAs with certain cancers. Those with certain cancers may have excess long-term mortality.
The adjusted OR for receiving any treatment was 0.33 among patients living in an area where at least 20% of the population was below the poverty line.
Short-term incidence of leukemia, lymphoma, and brain cancer may be higher in children who were hospitalized with pneumonia.
No dose-limiting toxicities were observed among the 6 patients who received ontuxizumab 4 mg/kg and 6 patients who received 8 mg/kg.
Consolidation with ATO allows a decrease in the cumulative dose of anthracycline while maintaining survival rates and a low risk of relapse among pediatric patients with APL.
The NCI and COG announced open enrollment for a study designed to evaluate the effectiveness of genetically matched targeted therapies for pediatric patients with cancer.
Pediatric patients with hematological malignancies who receive HSCT from an unrelated donor have greater benefit from a 15 mg/kg vs a 30 mg/kg dose of ATLG.
The US Food and Drug Administration granted Breakthrough Therapy Designation to burtomab for relapsed/refractory metastatic neuroblastoma.